China SXT Pharmaceuticals (China SXT Pharmaceuticals) Cash And Cash Equivalents : $11.47 Mil (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is China SXT Pharmaceuticals Cash And Cash Equivalents?

China SXT Pharmaceuticals's quarterly cash and cash equivalents increased from Sep. 2022 ($2.98 Mil) to Mar. 2023 ($17.37 Mil) but then stayed the same from Mar. 2023 ($17.37 Mil) to Sep. 2023 ($11.47 Mil).

China SXT Pharmaceuticals's annual cash and cash equivalents increased from Mar. 2021 ($13.33 Mil) to Mar. 2022 ($15.52 Mil) and increased from Mar. 2022 ($15.52 Mil) to Mar. 2023 ($17.37 Mil).

China SXT Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for China SXT Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China SXT Pharmaceuticals Cash And Cash Equivalents Chart

China SXT Pharmaceuticals Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash And Cash Equivalents

Get a 7-Day Free Trial

9.13

7.29

13.33

15.52

17.37

China SXT Pharmaceuticals Semi-Annual Data
	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Cash And Cash Equivalents	Get a 7-Day Free Trial									0.03	15.52	2.98	17.37	11.47

China SXT Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

China SXT Pharmaceuticals (NAS:SXTC) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

China SXT Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of China SXT Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China SXT Pharmaceuticals Inc (NAS:SXTC) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

2RY0:Germany

Address

No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300

Website

http://www.sxtchina.com

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, Advanced TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates a majority of its revenue from the People's Republic of China.